Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Monoamine oxidase, brain ageing and degenerative diseases.

Literature DB >> 2521790

Monoamine oxidase, brain ageing and degenerative diseases.

M Strolin Benedetti¹, P Dostert.

Abstract

Entities: Disease

Mesh：

Substances：
Monoamine Oxidase

Year: 1989 PMID： 2521790 DOI： 10.1016/0006-2952(89)90198-6

Source DB: PubMed Journal: Biochem Pharmacol ISSN： 0006-2952 Impact factor: 5.858

Keyword Cloud
Cited

× No keyword cloud information.

25 in total

1. Effect of aging on lazabemide binding, monoamine oxidase activity and monoamine metabolites in human frontal cortex.

Authors: M D Galva; G P Bondiolotti; M Olasmaa; G B Picotti
Journal: J Neural Transm Gen Sect Date: 1995

2. Antioxidant effect of peony seed oil on aging mice.

Authors: Xiao-Miao Han; Su-Xi Wu; Mei-Fang Wu; Xue-Feng Yang
Journal: Food Sci Biotechnol Date: 2017-12-12 Impact factor: 2.391

3. Timing of prenatal exposure to trauma and altered placental expressions of hypothalamic-pituitary-adrenal axis genes and genes driving neurodevelopment.

Authors: W Zhang; Q Li; M Deyssenroth; L Lambertini; J Finik; J Ham; Y Huang; K J Tsuchiya; P Pehme; J Buthmann; S Yoshida; J Chen; Y Nomura
Journal: J Neuroendocrinol Date: 2018-04 Impact factor: 3.627

Review 4. Neuroprotective and neurorestorative potential of propargylamine derivatives in ageing: focus on mitochondrial targets.

Authors: Orit Bar-Am; Tamar Amit; Moussa B Youdim; Orly Weinreb
Journal: J Neural Transm (Vienna) Date: 2015-04-10 Impact factor: 3.575

Review 9. Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and β-amyloid in ageing and Alzheimer's disease.

Authors: Orly Weinreb; Tamar Amit; Orit Bar-Am; Moussa B H Youdim
Journal: Br J Pharmacol Date: 2015-12-01 Impact factor: 8.739

Review 10. Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide.

Authors: M Mayersohn; T W Guentert
Journal: Clin Pharmacokinet Date: 1995-11 Impact factor: 6.447

Monoamine oxidase, brain ageing and degenerative diseases.

1. Effect of aging on lazabemide binding, monoamine oxidase activity and monoamine metabolites in human frontal cortex.

2. Antioxidant effect of peony seed oil on aging mice.

3. Timing of prenatal exposure to trauma and altered placental expressions of hypothalamic-pituitary-adrenal axis genes and genes driving neurodevelopment.

Review 4. Neuroprotective and neurorestorative potential of propargylamine derivatives in ageing: focus on mitochondrial targets.

Review 5. Selective MAO-B inhibitors: a lesson from natural products.

Review 6. Depression and senile dementia of the Alzheimer type: a role for moclobemide.

Review 7. Perspectives on MAO-B in aging and neurological disease: where do we go from here?

Review 8. Tryptamine: a metabolite of tryptophan implicated in various neuropsychiatric disorders.

Review 9. Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and β-amyloid in ageing and Alzheimer's disease.

Review 10. Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide.